Danny Rischin
Danny Rischin
Peter MacCallum Cancer Centre
Verified email at
Cited by
Cited by
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer
M Fukuoka, S Yano, G Giaccone, T Tamura, K Nakagawa, JY Douillard, ...
Journal of clinical oncology 41 (6), 1162-1171, 2023
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised …
B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ...
The Lancet 394 (10212), 1915-1928, 2019
PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma
MR Migden, D Rischin, CD Schmults, A Guminski, A Hauschild, KD Lewis, ...
New England Journal of Medicine 379 (4), 341-351, 2018
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five …
J Baselga, D Rischin, M Ranson, H Calvert, E Raymond, DG Kieback, ...
Journal of clinical oncology 20 (21), 4292-4302, 2002
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial
D Rischin, RJ Young, R Fisher, SB Fox, QT Le, LJ Peters, B Solomon, ...
Journal of clinical oncology 28 (27), 4142, 2010
Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02
LJ Peters, B O'Sullivan, J Giralt, TJ Fitzgerald, A Trotti, J Bernier, J Bourhis, ...
Journal of clinical oncology 28 (18), 2996-3001, 2010
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition
J Albanell, F Rojo, S Averbuch, A Feyereislova, JM Mascaro, R Herbst, ...
Journal of Clinical Oncology 20 (1), 110-124, 2002
Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer …
D Rischin, RJ Hicks, R Fisher, D Binns, J Corry, S Porceddu, LJ Peters
Journal of Clinical Oncology 24 (13), 2098-2104, 2006
Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non–small-cell …
MP Mac Manus, RJ Hicks, JP Matthews, A McKenzie, D Rischin, ...
Journal of Clinical Oncology 21 (7), 1285-1292, 2003
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck
JSW Stewart, EEW Cohen, L Licitra, CML Van Herpen, C Khorprasert, ...
Journal of clinical oncology 27 (11), 1864-1871, 2009
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of …
D Rischin, LJ Peters, B O'Sullivan, J Giralt, R Fisher, K Yuen, A Trotti, ...
Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments
B Solomon, RJ Young, D Rischin
Seminars in cancer biology 52, 228-240, 2018
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
SN Holden, SG Eckhardt, R Basser, R De Boer, D Rischin, M Green, ...
Annals of Oncology 16 (8), 1391-1397, 2005
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
MR Migden, NI Khushalani, ALS Chang, KD Lewis, CD Schmults, ...
The Lancet Oncology 21 (2), 294-305, 2020
Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo) radiotherapy in head and neck cancer
SV Porceddu, E Jarmolowski, RJ Hicks, R Ware, LA Weih, D Rischin, ...
Head & Neck: Journal for the Sciences and Specialties of the Head and Neck …, 2005
Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel
JD Shapiro, MJ Millward, D Rischin, M Michael, V Walcher, PA Francis, ...
Gynecologic oncology 63 (1), 89-93, 1996
Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the …
D Rischin, L Peters, R Fisher, A Macann, J Denham, M Poulsen, ...
Journal of Clinical Oncology 23 (1), 79-87, 2005
F‐18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high …
MP Mac Manus, RJ Hicks, DL Ball, V Kalff, JP Matthews, E Salminen, ...
Cancer 92 (4), 886-895, 2001
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
M Friedlander, KC Hancock, D Rischin, MJ Messing, CA Stringer, ...
Gynecologic oncology 119 (1), 32-37, 2010
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer
MS Anglesio, J George, H Kulbe, M Friedlander, D Rischin, C Lemech, ...
Clinical cancer research 17 (8), 2538-2548, 2011
The system can't perform the operation now. Try again later.
Articles 1–20